Celldex Therapeutics’ (CLDX) “Overweight” Rating Reaffirmed at Cantor Fitzgerald

Celldex Therapeutics (NASDAQ:CLDX)‘s stock had its “overweight” rating restated by investment analysts at Cantor Fitzgerald in a note issued to investors on Wednesday,Benzinga reports. They currently have a $67.00 price objective on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target would indicate a potential upside of 168.29% from the company’s current price.

Several other brokerages also recently commented on CLDX. HC Wainwright reiterated a “buy” rating and issued a $80.00 target price on shares of Celldex Therapeutics in a report on Thursday, December 19th. Citigroup assumed coverage on Celldex Therapeutics in a research report on Monday, October 7th. They set a “buy” rating and a $70.00 price target for the company. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $62.25.

Celldex Therapeutics Trading Up 1.4 %

Celldex Therapeutics stock traded up $0.35 during midday trading on Wednesday, reaching $24.97. The stock had a trading volume of 18,918 shares, compared to its average volume of 1,046,135. The company has a fifty day moving average price of $25.66 and a two-hundred day moving average price of $31.32. The company has a market capitalization of $1.66 billion, a P/E ratio of -9.65 and a beta of 1.62. Celldex Therapeutics has a 12 month low of $22.17 and a 12 month high of $53.18.

Insiders Place Their Bets

In related news, CEO Anthony S. Marucci purchased 11,500 shares of the company’s stock in a transaction dated Monday, November 11th. The shares were purchased at an average cost of $26.82 per share, with a total value of $308,430.00. Following the transaction, the chief executive officer now directly owns 40,284 shares in the company, valued at $1,080,416.88. This trade represents a 39.95 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 3.80% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Celldex Therapeutics

Large investors have recently modified their holdings of the stock. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Celldex Therapeutics during the 2nd quarter valued at about $76,000. KBC Group NV increased its position in shares of Celldex Therapeutics by 31.2% during the 3rd quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company’s stock valued at $71,000 after purchasing an additional 495 shares during the last quarter. AQR Capital Management LLC lifted its stake in shares of Celldex Therapeutics by 23.7% in the 2nd quarter. AQR Capital Management LLC now owns 7,857 shares of the biopharmaceutical company’s stock worth $291,000 after purchasing an additional 1,504 shares during the period. Handelsbanken Fonder AB boosted its holdings in shares of Celldex Therapeutics by 23.2% in the third quarter. Handelsbanken Fonder AB now owns 13,800 shares of the biopharmaceutical company’s stock worth $469,000 after buying an additional 2,600 shares during the last quarter. Finally, Point72 DIFC Ltd boosted its holdings in shares of Celldex Therapeutics by 101.7% in the third quarter. Point72 DIFC Ltd now owns 14,114 shares of the biopharmaceutical company’s stock worth $480,000 after buying an additional 7,116 shares during the last quarter.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.